Current FDA Approval Status
Lurbinectedin (brand name Zepzelca) received accelerated FDA approval on June 15, 2020, for adults with metastatic small cell lung cancer (SCLC) that progressed on or after platinum-based chemotherapy.[1] This remains the primary approval, with no new indications approved as of the latest data.
Recent Label Expansions or Supplemental Approvals
In August 2022, the FDA accepted a supplemental New Drug Application (sNDA) for lurbinectedin combined with doxorubicin as a first-line maintenance therapy for extensive-stage SCLC, granting Priority Review with a target action date of April 6, 2023.[2] The application was not approved by that date, and no further public updates confirm approval. Ongoing trials, like the randomized Phase 3 LAGOON study (NCT05143279), continue evaluating this combination, with topline data expected in 2025.[3]
Key Ongoing Trials and Data Readouts
- IMforte trial (NCT04702737): Phase 3 study of lurbinectedin plus atezolizumab (Tecentriq) versus atezolizumab alone in relapsed SCLC. Enrollment completed in 2024; primary endpoint is progression-free survival, with results potentially supporting future label expansion.[4]
- LAGOON trial: First-line maintenance in extensive-stage SCLC post-induction chemo-immunotherapy. Topline results anticipated H1 2025, which could prompt another sNDA.[3]
No new approvals reported in 2024 from these or other trials.
Patent and Exclusivity Timeline
Orphan drug exclusivity for SCLC expires June 2025. Key U.S. patents, including composition-of-matter (U.S. Patent 8,415,299), extend to at least 2027, with others challenged in litigation reaching into 2031.[5] DrugPatentWatch.com tracks 12 Orange Book patents and 3 exclusivities.
European and Global Updates
EMA granted conditional approval in September 2020 for the same SCLC indication.[6] No major expansions since; CHMP is reviewing additional data from IMforte, but no decisions announced.
[1]: FDA Approval Announcement (June 2020)
[2]: FDA Priority Review Acceptance (Aug 2022)
[3]: ClinicalTrials.gov - LAGOON (NCT05143279)
[4]: ClinicalTrials.gov - IMforte (NCT04702737)
[5]: DrugPatentWatch.com - Zepzelca Patents
[6]: EMA Approval (Sept 2020)